Year-over-year earnings per share growth for the last twelve months: Opus Genetics (IRD)

Opus Genetics (IRD) - corporate logo

The stability of Opus Genetics Inc (IRD) is confirmed by a resilient biomaterial supply chain via air carriers, which is further supported by the quarterly earnings per share history, where the -85.00 mark characterizes this parameter. The operational base relies on outsourcing tests to external partners and implementing automated bioreactor platforms to control the vector cultivation environment.

Opus Genetics, Inc. (IRD) Year-over-year net earnings per share trend for the last twelve months: for the period 10/25/2024 - 11/11/2026

Summary analytical data breakdowns for Opus Genetics Inc (IRD)

- market value and analyst target forecast:
Price Chart opusgtx.com|IRD - Analyst Median Target
- company stock exchange capitalization indicators:
Market Value Opus Bio|IRD - Total Enterprise Value
- book capitalization data:
Net Assets per Single Share Opus Genetics|IRD - Net Asset Value|Market Cap to Net Assets Ratio opusgtx.com|IRD - Company Total Assets
- company liabilities and liquidity data:
Debt to Equity Opus Genetics Inc|IRD - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Ratio opusgtx.com|IRD - Aggregate Debt Obligations|Debts to Book Capitalization Opus Bio|IRD - Long-Term Indebtedness|Company Short-Term Debts Opus Genetics|Quick Liquidity opusgtx.com
- earnings and market multiples details:
IRD - Company Profit|Projected Future Earnings Opus Genetics Inc|IRD - Market Cap to Earnings|Projected Price to Earnings opusgtx.com|IRD - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple Opus Bio|IRD - Operating income before deduction of amortization|Net earnings per share (EPS TTM) Opus Genetics|IRD - Net earnings per share for the last 12 months|Year-over-year earnings per share growth for the last twelve months opusgtx.com|IRD - Expected net earnings per share growth this year|Expected earnings per share growth for next year Opus Genetics Inc
Summary company analytics:Opus Genetics, Inc. - IRD
Manufactured product of Opus Genetics

The development dynamics of gene therapies for hereditary retinal diseases by Opus Genetics Inc (IRD) are reflected in the quarterly earnings per share growth chart. This indicator measures the percentage change in net income per share relative to the previous period, allowing investors to assess the effectiveness of monetizing niche medical segments and the business's fundamental ability to scale return on capital.

Competitors of Opus Genetics Inc

Alcon (ALC) - Year-over-year earnings per share growth for the last twelve months|BLCO - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Glaukos Corp.|Earnings per share growth in annualized terms for the last twelve months Apellis Corp APLS|Year-over-year earnings per share growth for the last twelve months Belite Bio (BLTE)|OCUL: Year-over-year net earnings per share trend for the last twelve months|Harrow - Year-over-year net earnings per share growth for the last 12 months|Quarterly EPS earnings growth Viridian Therapeutics Inc VRDN|LENZ - Year-over-year earnings per share growth for the last twelve months|Year-over-year net earnings per share change for the last twelve months Oaktree Specialty Lending OCS|EYPT (EyePoint Pharmaceuticals) - Year-over-year net earnings per share growth for the last 12 months|kodiak.com - Year-over-year earnings per one share growth for the last 12 months|ALDX (Aldeyra Therapeutics Inc.) - Quarterly EPS earnings growth|KALA - Net earnings per share growth for the trailing year|Quarterly EPS earnings growth OKYO|ADVM - Earnings per share growth in annualized terms for the last twelve months|Year-over-year earnings per share growth for the last twelve months Outlook Therapeutics OTLK|CLSD: Year-over-year earnings per share growth for the last 12 months|NovaBay - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Kiora Pharmaceuticals|ALIM (alimerasciences.com) - Year-over-year net earnings per share growth for the last 12 months|EYEN: Year-over-year earnings per share growth rate for the last twelve months|GHSI (Guardion Health Science) - Quarterly EPS earnings growth|ocuphire.com (OCUP) - Year-over-year net earnings per share change for the last twelve months|Quarterly EPS earnings growth OPT